熱門資訊> 正文

AgomAb Therapeutics NV报告1H结果

2026-08-07 22:16

AgomAb Therapeutics(AGMB) 0

AgomAb Therapeutics NV press release (AGMB): 1H Cash, cash equivalents and short-term cash investments totaled €252.0 million as of June 30, 2026.
Net loss was €31.0 million for the six months ended June 30, 2026, compared to €26.9 million for the six months ended June 30, 2025.

More on AgomAb Therapeutics NV

AgomAb Therapeutics: High Risk, High Reward Stock
Historical earnings data for AgomAb Therapeutics NV
Financial information for AgomAb Therapeutics NV

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。